*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Prof. Alan Spivey, Imperial College, London
Synthesis directed at the disruption of protein-protein interactions - asthma and cancer related targets
School Colloquium
Two projects will be described, both relating to synthetic efforts to develop small molecules to disrupt protein-protein interactions (PPIs) of potential medicinal importance.
The first PPI we have been investigating is that between Immunolobulin E (IgE) (a protein found e.g. in the blood) and its high affinity receptor FceRI (a membrane-bound protein found e.g. on the surface of mast cells and basophils). This PPI is central to the allergic signal transduction cascade and so is a key target for potential anti-asthma therapeutics. Proof of principle that this strategy can be effective, and does not suffer from unacceptable side-effects, comes from the successful clinical use of the monoclonal antibody Omalizumab (Xolair) which is indicated for severe persistent asthma and operates by sequestering IgE in the blood and preventing binding to FceRI. However, its high cost and non-oral mode of delivery has fuelled interest in the development of alternative, small molecule antagonists of this PPI. We have been investigating approaches to disrupting this PPI based on both constrained peptides based on a hot spot epitope of IgE1 and based on a natural product antagonist, aspercyclide A.2,3
The second PPI we have been investigating is that between the Nuclear Receptor (NR) Liver Receptor Homologue-1 (LRH-1) and its various co-activator and co-repressor proteins such as the transcription activator Peroxisome Proliferator-Activated Receptor-γ Co-activator (PGC)-1a. The regulation of transcription by these complexes has potential therapeutic benefit in the context of breast cancer where LRH-1 has been implicated as having a role in modulating estrogen signalling.4 The PPI centres on an interaction between an LXXLL a-helical motif in the co-activator and a complimentary groove in the co-activator binding domain (AF2) of the NR. We have been investigating approaches to disrupting this PPI based on rational design of a new a-helix mimetic motif.
References
1.
D.A. Offermann, J.E. McKendrick, J.J.P. Sejberg, B. Mo, M.D. Holdom, B.A. Helm,
R.J. Leatherbarrow, A.J. Beavil, B.J. Sutton, A.C. Spivey, 'Synthesis and
Incorporation into Cyclic Peptides of Tolan Amino Acids and their Hydrogenated
Congeners: Construction of an Array of A-B-loop Mimetics of the Cε3 Domain of
Human IgE', J. Org.
Chem. 2012, 77, ASAP.
2.
J.L. Carr, D.A.
Offermann, M.D.
Holdom, P. Dusart, A.J.P. White, A.J. Beavil, R.J. Leatherbarrow, S.D. Lindell, B.J. Sutton, A.C. Spivey 'Total
Synthesis of (+/-)-Aspercyclide A and its C19 Methyl Ether' Chem. Comm. 2010, 1824-1826.
3.
J.L. Carr, J.J.P. Sejberg, F. Saab, M.D. Holdom, A.M. Davies, A.J.P. White,
R.J.Leatherbarrow, A.J. Beavil, B.J. Sutton, S.D. Lindell, A.C. Spivey,
'Synthesis of the C19 Methyl Ether of Aspercyclide A via Germyl-Stille
Macrocyclisation and ELISA Evaluation of Both Enantiomers Following Optical
Resolution', Org. Biomol. Chem. 2011, 9,
6814-6824.
4.
Thiruchelvam, P.T.; Lai, F.F.; Hua, H.;
Thomas, R.S.; Hurtado, A.; Hudson, W.; Bayly,A.R.; Kyle, F.J.; Periyasamy, M.;
Photiou, A.; Spivey,A.C.; Ortlund,E.A.; Whitby,R.J.; Carroll, J.S.; Coombes,
R.C.; Buluwela, L.; Ali, S. 'The liver receptorhomolog-1 regulates estrogen
receptor expression in breast cancer cells' Breast
Cancer Res. Treat. 2010,
127, 385-396.
